Trials / Completed
CompletedNCT02019056
Efficacy and Safety of MG in the Patients With Alcoholic Fatty Liver Disease and Alcoholic Hepatitis
A Multicenter, Randomized, Double-blind, Placebo-controlled,Phase 2 Study to Evaluate the Efficacy, Safety of MG in Patients With Alcoholic Fatty Liver Disease and Alcoholic Hepatitis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 90 (actual)
- Sponsor
- PharmaKing · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The Purpose of A Multicenter, Randomized, Double-blind, Placebo-controlled to Evaluate the Efficacy, Safety and Pharmacokinetics of MG in Patients With alcoholic Fatty Liver Disease and Alcoholic Hepatitis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Placebo /bid P.O | |
| DRUG | MG-1 | |
| DRUG | MG-2 : MG1000mg, Placebo /bid P.O | |
| DRUG | metadoxine |
Timeline
- Start date
- 2010-11-01
- Primary completion
- 2014-12-01
- Completion
- 2014-12-01
- First posted
- 2013-12-24
- Last updated
- 2015-04-29
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT02019056. Inclusion in this directory is not an endorsement.